Matthew-Wood syndrome
MONDO:0011010Matthew-Wood syndrome is a rare clinical entity including as main characteristics anophthalmia or severe microphthalmia, and pulmonary hypoplasia or aplasia.
Also known as: MCOPS9, Matthew-Wood syndrome, anophthalmia-pulmonary hypoplasia syndrome, microphthalmia syndromic type 9, microphthalmia, syndromic type 9, syndromic microphthalmia type 9, Matthew Wood syndrome, anophthalmia, clinical, with mild Facial Dysmorphism and variable malformations of the lung, heart, and diaphragm
5 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Double antibody attack: new hope for tough pancreatic cancer?
Disease control OngoingThis phase 2 trial tests whether adding a new antibody called HLX22 to standard treatment (trastuzumab plus chemotherapy) can shrink tumors and improve survival in people with HER2-positive pancreatic cancer that has spread. The study enrolls 45 adults who have not had prior trea…
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Experimental drug offered to cancer patients with severe wasting
Symptom relief NO_LONGER_AVAILABLEThis expanded access program gives seriously ill adults with advanced pancreatic cancer and cachexia (severe weight loss and muscle wasting) access to the experimental drug mifomelatide. Patients receive a daily injection for up to 13 weeks. The goal is to provide a potential tre…
Sponsor: Endevica Bio • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC